These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 1848441)

  • 1. Pharmacokinetics and biodistribution of technetium 99m labelled standard heparin and a low molecular weight heparin (enoxaparin) after intravenous injection in normal volunteers.
    Laforest MD; Colas-Linhart N; Guiraud-Vitaux F; Bok B; Bara L; Samama M; Marin J; Imbault F; Uzan A
    Br J Haematol; 1991 Feb; 77(2):201-8. PubMed ID: 1848441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the pharmacokinetics of enoxaparin (Clexane) and unfractionated heparin.
    Dawes J
    Acta Chir Scand Suppl; 1990; 556():68-74. PubMed ID: 1963020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of low molecular weight heparins.
    Bara L; Samama M
    Acta Chir Scand Suppl; 1990; 556():57-61. PubMed ID: 1963018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of low molecular weight heparins.
    Bara L; Samama M
    Acta Chir Scand Suppl; 1988; 543():65-72. PubMed ID: 2847460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers.
    Azizi M; Veyssier-Belot C; Alhenc-Gelas M; Chatellier G; Billaud-Mesguish E; Fiessinger JN; Aiach M
    Br J Clin Pharmacol; 1995 Dec; 40(6):577-84. PubMed ID: 8703665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of a low molecular weight heparin (enoxaparin) after subcutaneous injection, comparison with unfractionated heparin--a three way cross over study in human volunteers.
    Bendetowicz AV; Béguin S; Caplain H; Hemker HC
    Thromb Haemost; 1994 Mar; 71(3):305-13. PubMed ID: 8029794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unfractionated heparin and CY 216: pharmacokinetics and bioavailabilities of the antifactor Xa and IIa effects after intravenous and subcutaneous injection in the rabbit.
    Briant L; Caranobe C; Saivin S; Sié P; Bayrou B; Houin G; Boneu B
    Thromb Haemost; 1989 Jun; 61(3):348-53. PubMed ID: 2552603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and pharmacodynamic characterization of a medium-molecular-weight heparin in comparison with UFH and LMWH.
    Alban S; Welzel D; Hemker HC
    Semin Thromb Hemost; 2002 Aug; 28(4):369-78. PubMed ID: 12244484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins.
    Brieger D; Dawes J
    Thromb Haemost; 1997 Feb; 77(2):317-22. PubMed ID: 9157589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and tissue distribution of 99mTc-labelled enoxaparin in the rat: evaluation of dosimetry parameters.
    Colas Linhart N; Laforest MD; Guiraud-Vitaux F; Gardin I; Petiet A; Berthelot JL; Bok B
    Biomed Pharmacother; 1990; 44(6):317-23. PubMed ID: 2171691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative pharmacodynamic time-course of bemiparin and enoxaparin in healthy volunteers.
    Antonijoan RM; Rico S; Martínez-González J; Borrell M; Valcarcel D; Fontcuberta J; Barbanoj MJ
    Int J Clin Pharmacol Ther; 2009 Dec; 47(12):726-32. PubMed ID: 19954711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterisation of persistent anti-Xa activity following administration of the low molecular weight heparin enoxaparin sodium (Clexane).
    Brieger D; Dawes J
    Thromb Haemost; 1994 Aug; 72(2):275-80. PubMed ID: 7831665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of Certoparin During In Vitro and In Vivo Dialysis.
    Krieter DH; Fink S; Dorsch O; Harenberg J; Melzer N; Wanner C; Lemke HD
    Artif Organs; 2015 Nov; 39(11):951-9. PubMed ID: 25900127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of low-molecular-weight heparin and unfractionated heparin during elective aortobifemoral bypass grafting.
    Kroneman H; Eikelboom BC; Knot EA; de Smit P; Groenland TH; de Maat MP; Van Urk H
    J Vasc Surg; 1991 Aug; 14(2):208-14. PubMed ID: 1650406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic considerations on Orgaran (Org 10172) therapy.
    Danhof M; de Boer A; Magnani HN; Stiekema JC
    Haemostasis; 1992; 22(2):73-84. PubMed ID: 1379967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of UH and LMWH are similar with respect to antithrombin activity.
    Morris TA; Jacobson A; Marsh JJ; Lane JR
    Thromb Res; 2005; 115(1-2):45-51. PubMed ID: 15567452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term persistence of biological activity following administration of Enoxaparin sodium (clexane) is due to sequestration of antithrombin-binding low molecular weight fragments--comparison with unfractionated heparin.
    Brieger D; Dawes J
    Thromb Haemost; 1996 May; 75(5):740-6. PubMed ID: 8725716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absence of transplacental passage of the low molecular weight heparin enoxaparin.
    Dimitrakakis C; Papageorgiou P; Papageorgiou I; Antzaklis A; Sakarelou N; Michalas S
    Haemostasis; 2000; 30(5):243-8. PubMed ID: 11251331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of heparin and low molecular weight heparin fragment (Fragmin) in rabbits with impaired renal or metabolic clearance.
    Palm M; Mattsson C
    Thromb Haemost; 1987 Oct; 58(3):932-5. PubMed ID: 2829379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers.
    Sanderink GJ; Le Liboux A; Jariwala N; Harding N; Ozoux ML; Shukla U; Montay G; Boutouyrie B; Miro A
    Clin Pharmacol Ther; 2002 Sep; 72(3):308-18. PubMed ID: 12235452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.